Cell Signaling Technology

Product Pathways - TGF-beta/Smad Signaling

Human BMP2 #4697

MW Source Purity
26 recombinant human BMP2 expressed in E. coli >95%

Description

Recombinant human BMP-2 was expressed in E. coli and is supplied in a lyophilized form. A greater than 95% purity was determined by reverse-phase HPLC and SDS-PAGE.

Concentration and Specific Activity

10 μg lyophilized, ED50 less than 50 ng/ml

Western Blotting

Western Blotting

Western blot analysis of extracts from serum-starved HT-1080 cells treated for 30 minutes with various concentrations of Human BMP2 using Phospho-Smad1/5 (Ser463/465) (41D10) Rabbit mAb #9516 (upper) and Smad1 Antibody #9743 (lower).

Directions for Use

The working concentration of BMP-2 generally ranges from 20-50 ng/ml.

Background

Bone morphogenetic proteins (BMPs) were first identified as molecules that can induce ectopic bone and cartilage formation (1,2). BMPs are synthesized as precursor proteins which are processed by cleavage to produce mature proteins. BMPs initiate signaling by binding to a receptor complex containing type I and type II serine/threonine receptor kinases that then phosphorylate Smad (mainly Smad1, 5 and 8), resulting in the translocation of Smad to the nucleus. BMP was also reported to activate MAPK pathways in some systems (3,4).

  1. Wang, E.A. et al. (1988) Proc Natl Acad Sci USA 85, 9484-8.
  2. Wozney, J.M. et al. (1988) Science 242, 1528-34.
  3. Kawabata, M. et al. (1998) Cytokine Growth Factor Rev 9, 49-61.
  4. Nohe, A. et al. (2004) Cell Signal 16, 291-9.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

This product is for in vitro research use only and is not intended for use in humans or animals. This product is not intended for use as therapeutic or in diagnostic procedures.

Products